Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
23.87
+0.03 (0.13%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Oruka Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
835.42M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 46.86M | 42.97M | 1,105.27% |
Dec 31, 2006 | 3.89M | 3.34M | 613.39% |
Dec 31, 2005 | 545.00K | 350.00K | 179.49% |
Dec 31, 2004 | 195.00K | -829.00K | -80.96% |
Dec 31, 2003 | 1.02M | -24.53M | -95.99% |
Dec 31, 2002 | 25.55M | 964.00K | 3.92% |
Dec 31, 2001 | 24.59M | 8.99M | 57.59% |
Dec 31, 2000 | 15.60M | 9.21M | 143.93% |
Dec 31, 1999 | 6.40M | -3.19M | -33.30% |
Dec 31, 1998 | 9.59M | 3.39M | 54.70% |
Dec 31, 1997 | 6.20M | 5.77M | 1,355.16% |
Dec 31, 1996 | 426.00K | -1.70M | -79.97% |
Dec 31, 1995 | 2.13M | 2.08M | 4,154.00% |
Dec 31, 1994 | 50.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionORKA News
- 1 day ago - Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 14 days ago - Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewsWire
- 4 weeks ago - ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics - GlobeNewsWire
- 4 weeks ago - ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics - GlobeNewsWire
- 5 weeks ago - ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics - GlobeNewsWire
- 2 months ago - ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO - Business Wire